Skip to main content
Exact Dx synthetic data · demonstration

Staff surface Definitions and reviews

Definition library

Every executable definition and catalogue entry, with the threshold quoted from its source. All are drafts pending clinical and coding review; a definition shows as reviewed only after an approval is recorded. Default set library_default_set@1.0.

Coder worklist

Cancer-treatment adverse-event grading scale (NCI CTCAE): off by default

CTCAE grades describe adverse events in people receiving cancer treatment, usually in trials; they are not diagnostic criteria, and several grades depend on the laboratory reference range or on clinical descriptors that are not encoded. Using them outside that setting is a local decision for the clinical reviewer.

Current: Off (default) When on, grading entries are shown only as "another published definition gives …" or as values needing clinical judgement; they never raise a "not stated" item.

CDI or coding staff can change this setting and record reviews: switch the demo user.

48 of 66 shown · open an entry for its source, threshold and review.

Diabetes diagnostic thresholds and the confirmation rule (ADA Standards of Care 2026) ada2026_diabetes@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Diabetes mellitus
Tier
1
Use here
default set (diabetes)
Edition
Standards of Care in Diabetes—2026 (2026)
Second source
none opened · not found: The WHO diabetes fact sheet (dated 11 November 2026) states no numeric thresholds; the WHO 2006/2011 reports were not opened. No independent second source was opened.
Contested
no: ADA thresholds match long-standing WHO thresholds for A1C and FPG, but WHO's current text was not opened; the A1C criterion is less sensitive in some populations (ADA text).

American Diabetes Association Professional Practice Committee, 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026

ada2026_diabetes@1.0
Table 2.1: A1C ≥6.5% (≥48 mmol/mol); FPG ≥126 mg/dL (≥7.0 mmol/L); 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during OGTT; random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic symptoms of hyperglycemia or hyperglycemic crisis. In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal results from different tests ... or the same test at two different time points.

Standards of Care in Diabetes—2026 (2026) · Table 2.1 Criteria for the diagnosis of diabetes in nonpregnant individuals · source

Review

No review recorded yet.

Hypoglycaemia level (ADA Standards of Care 2026) ada2026_hypoglycaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypoglycaemia
Tier
1
Use here
default set (hypoglycaemia)
Edition
Standards of Care in Diabetes—2026 (2026)
Second source
International Hypoglycaemia Study Group 2017 · partly agrees: Agrees on level 2 (<3.0 mmol/L, <54 mg/dL) and on level 3 being clinical; disagrees on level 1 at exactly 70 mg/dL ('3.9 mmol/l (70 mg/dl) or less').
Contested
yes: The International Hypoglycaemia Study Group (2017) sets level 1 at 'a glucose alert value of 3.9 mmol/l (70 mg/dl) or less', i.e. it includes exactly 70 mg/dL; ADA 2026 uses '<70'. CTCAE uses other cut-offs.

American Diabetes Association Professional Practice Committee, 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026

ada2026_hypoglycaemia@1.0
Level 1: Glucose <70 mg/dL (<3.9 mmol/L) and ≥54 mg/dL (≥3.0 mmol/L). Level 2: Glucose <54 mg/dL (<3.0 mmol/L). Level 3: A severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycemia

Standards of Care in Diabetes—2026 (2026) · Table 6.4 Classification of hypoglycemia · source

Review

No review recorded yet.

Prediabetes ranges (ADA Standards of Care 2026) ada2026_prediabetes@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Prediabetes
Tier
1
Use here
default set (prediabetes)
Edition
Standards of Care in Diabetes—2026 (2026)
Second source
none opened · not found: No independent second source was opened.
Contested
yes: Other bodies (for example WHO) are understood to use a different impaired fasting glucose range and not to use an A1C prediabetes range; those texts were not opened, so no other thresholds are recorded. Review item.

American Diabetes Association Professional Practice Committee, 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026

ada2026_prediabetes@1.0
A1C 5.7–6.4% (39–47 mmol/mol); FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG); 2-h PG during 75-g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (IGT)

Standards of Care in Diabetes—2026 (2026) · Table 2.2 Criteria defining prediabetes in nonpregnant individuals · source

Review

No review recorded yet.

Severe hypercholesterolaemia, LDL-C ≥190 mg/dL (2018 AHA/ACC cholesterol guideline) aha2018_severe_hypercholesterolaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Severe hypercholesterolaemia
Tier
1
Use here
default set (ldl)
Edition
2018 (2018)
Second source
National Heart, Lung, and Blood Institute, National Cholesterol Education Program (NIH Publication No. 01-3670) 2001 · agrees: ATP III calls ≥190 mg/dL 'very high'.
Contested
no: Same 190 mg/dL boundary as ATP III 'very high'.

American Heart Association / American College of Cardiology and partner societies, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

aha2018_severe_hypercholesterolaemia@1.0
Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L])

2018 (2018) · Section 4.2 heading; Top 10 Take-Home Message 4 · source

Review

No review recorded yet.

Low HDL cholesterol (NCEP ATP III, 2001) atp3_hdl@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Low HDL cholesterol
Tier
1
Use here
not run by default: Only a superseded edition (2001) is encoded and no current edition was opened; not run by default.
Edition
ATP III (May 2001) (2001) (a newer edition exists)
Second source
none opened · not found: No independent second source was opened.
Contested
yes: Sex-specific HDL thresholds are used in other ATP III criteria (metabolic syndrome) and by other bodies; not encoded.

National Heart, Lung, and Blood Institute, National Cholesterol Education Program (NIH Publication No. 01-3670), Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary

atp3_hdl@1.0
HDL Cholesterol <40 Low; ≥60 High

ATP III (May 2001) (2001) · Table 2 (PDF page 13) · source

Review

No review recorded yet.

LDL cholesterol classification (NCEP ATP III, 2001) atp3_ldl@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypercholesterolaemia (LDL)
Tier
1
Use here
alternative beside ldl: Superseded edition; shown only as 'another published definition gives' beside the current primary (aha2018_severe_hypercholesterolaemia).
Edition
ATP III (May 2001) (2001) (a newer edition exists)
Second source
American Heart Association / American College of Cardiology and partner societies 2018 · partly agrees: The 2018 guideline agrees on the 190 mg/dL boundary and lists LDL-C 160-189 mg/dL as a risk-enhancing factor; it has no 'optimal'/'borderline' classes.
Contested
no: Classification of an older edition; the 2018 guideline uses LDL ≥190 mg/dL for severe hypercholesterolaemia, agreeing at that boundary.

National Heart, Lung, and Blood Institute, National Cholesterol Education Program (NIH Publication No. 01-3670), Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary

atp3_ldl@1.0
LDL Cholesterol <100 Optimal; 100-129 Near optimal/above optimal; 130-159 Borderline high; 160-189 High; ≥190 Very high

ATP III (May 2001) (2001) · Table 2 (PDF page 13) · source

Review

No review recorded yet.

Total cholesterol classification (NCEP ATP III, 2001) atp3_total_cholesterol@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypercholesterolaemia (total)
Tier
1
Use here
not run by default: Only a superseded edition (2001) is encoded and no current edition was opened; not run by default.
Edition
ATP III (May 2001) (2001) (a newer edition exists)
Second source
none opened · not found: No independent second source was opened.
Contested
no: Older edition; no current US classification of total cholesterol was opened.

National Heart, Lung, and Blood Institute, National Cholesterol Education Program (NIH Publication No. 01-3670), Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary

atp3_total_cholesterol@1.0
Total Cholesterol <200 Desirable; 200-239 Borderline high; ≥240 High

ATP III (May 2001) (2001) · Table 2 (PDF page 13) · source

Review

No review recorded yet.

Triglyceride classification (NCEP ATP III, 2001) atp3_triglycerides@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypertriglyceridaemia
Tier
1
Use here
not run by default: Only a superseded edition (2001) is encoded and no current edition was opened; not run by default.
Edition
ATP III (May 2001) (2001) (a newer edition exists)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · partly agrees: Both start abnormal at 150 mg/dL; bands above differ.
Contested
yes: CTCAE grades triglycerides differently (500 mg/dL is CTCAE grade 2, ATP III very high); the 2018 guideline's moderate/severe hypertriglyceridaemia definitions were not found in the opened text.

National Heart, Lung, and Blood Institute, National Cholesterol Education Program (NIH Publication No. 01-3670), Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary

atp3_triglycerides@1.0
Normal triglycerides: <150 mg/dL; Borderline-high triglycerides: 150-199 mg/dL; High triglycerides: 200-499 mg/dL; Very high triglycerides: ≥500 mg/dL

ATP III (May 2001) (2001) · Classification of serum triglycerides (PDF page 28) · source

Review

No review recorded yet.

ARDS oxygenation severity by PaO2/FiO2 (Berlin Definition 2012, numeric part only) berlin2012_ards_pf@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Acute respiratory distress syndrome (oxygenation component)
Tier
1
Use here
alternative beside oxygenation: Superseded by the 2024 global definition; shown only as an alternative beside global2024_ards_intubated_pf.
Edition
Berlin Definition 2012 (2012) (a newer edition exists)
Second source
American Thoracic Society-led global consensus (Am J Respir Crit Care Med 2024;209(1):37-47) 2024 · agrees: Same PaO2/FiO2 bands for intubated patients; the global definition adds SpO2/FiO2 alternatives and a non-intubated category.
Contested
no: The bands are shared by the 2024 global definition for intubated patients.

ARDS Definition Task Force (European Society of Intensive Care Medicine initiative, endorsed by ATS and SCCM), Acute respiratory distress syndrome: the Berlin Definition

berlin2012_ards_pf@1.0
mild (200 mm Hg < PaO2/FIO2 ≤ 300 mm Hg), moderate (100 mm Hg < PaO2/FIO2 ≤ 200 mm Hg), and severe (PaO2/FIO2 ≤ 100 mm Hg)

Berlin Definition 2012 (2012) · Abstract (Europe PMC record of PMID:22797452) · source

Review

No review recorded yet.

Adult BMI categories: underweight, healthy weight, overweight, obesity classes 1-3 (CDC) cdc_adult_bmi@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Obesity / overweight / underweight
Tier
1
Use here
default set (bmi)
Edition
page dated March 19, 2024 (2024)
Second source
World Health Organization 2026 · agrees: WHO agrees on 25 and 30 for adults; WHO applies them from age 18, CDC from age 20; the WHO fact sheet does not give classes or underweight.
Contested
yes: BMI cut-offs are population-specific (WHO 2004 expert consultation proposed lower action points for Asian populations; not opened) and BMI does not measure adiposity directly; the CDC page applies the categories 'regardless of age, sex, or race' for adults.

Centers for Disease Control and Prevention, Adult BMI Categories

cdc_adult_bmi@1.0
Underweight: Less than 18.5; Healthy Weight: 18.5 to less than 25; Overweight: 25 to less than 30; Obesity: 30 or greater; Class 1 Obesity: 30 to less than 35; Class 2 Obesity: 35 to less than 40; Class 3 Obesity (Severe Obesity): 40 or greater

page dated March 19, 2024 (2024) · Adult BMI categories table · source

Review

No review recorded yet.

Lymphocyte count decreased, grade (CTCAE v5.0) ctcae5_lymphopenia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Lymphopenia
Tier
1
Use here
not run by default
Edition
v5.0 (2017) (a newer edition exists)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

ctcae5_lymphopenia@1.0
Grade 1: <LLN - 800/mm3; <LLN - 0.8 x 10e9/L. Grade 2: <800 - 500/mm3; <0.8 - 0.5 x 10e9 /L. Grade 3: <500 - 200/mm3; <0.5 - 0.2 x 10e9 /L. Grade 4: <200/mm3; <0.2 x 10e9 /L

v5.0 (2017) · PDF page 88 (5x7 quick reference), term 'Lymphocyte count decreased' (published November 27, 2017) · source

Review

No review recorded yet.

Neutrophil count decreased, grade (CTCAE v5.0) ctcae5_neutropenia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Neutropenia
Tier
1
Use here
not run by default
Edition
v5.0 (2017) (a newer edition exists)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · disagrees: CTCAE v6.0 (same body, not independent) shifted the bands (grade 4 <100/mm3). No independent body grades neutropenia on this scale.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

ctcae5_neutropenia@1.0
Grade 1: <LLN - 1500/mm3; <LLN - 1.5 x 10e9 /L. Grade 2: <1500 - 1000/mm3; <1.5 - 1.0 x 10e9 /L. Grade 3: <1000 - 500/mm3; <1.0 - 0.5 x 10e9 /L. Grade 4: <500/mm3; <0.5 x 10e9 /L

v5.0 (2017) · PDF page 88 (5x7 quick reference), term 'Neutrophil count decreased' (published November 27, 2017) · source

Review

No review recorded yet.

Platelet count decreased, grade (CTCAE v5.0) ctcae5_thrombocytopenia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Thrombocytopenia
Tier
1
Use here
not run by default
Edition
v5.0 (2017) (a newer edition exists)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · disagrees: CTCAE v6.0 (same body, not independent) moved the grade 3/4 boundary to 10,000/mm3.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

ctcae5_thrombocytopenia@1.0
Grade 1: <LLN - 75,000/mm3; <LLN - 75.0 x 10e9 /L. Grade 2: <75,000 - 50,000/mm3; <75.0 - 50.0 x 10e9 /L. Grade 3: <50,000 - 25,000/mm3; <50.0 - 25.0 x 10e9 /L. Grade 4: <25,000/mm3; <25.0 x 10e9 /L

v5.0 (2017) · PDF page 89 (5x7 quick reference), term 'Platelet count decreased' (published November 27, 2017) · source

Review

No review recorded yet.

Acidosis grade by blood pH (CTCAE v6.0) ctcae6_acidosis@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Acidaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_acidosis@1.0
Grade 1: pH <normal, but >=7.3. Grade 2: -. Grade 3: pH <7.3. Grade 4: Life-threatening consequences

v6.0 (2025) · PDF page 174, term 'Acidosis' (published July 22, 2025) · source

Review

No review recorded yet.

Alkalosis grade by blood pH (CTCAE v6.0) ctcae6_alkalosis@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Alkalaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_alkalosis@1.0
Grade 1: pH >normal, but <=7.5. Grade 2: -. Grade 3: pH >7.5. Grade 4: Life-threatening consequences

v6.0 (2025) · PDF page 174, term 'Alkalosis' (published July 22, 2025) · source

Review

No review recorded yet.

Anaemia grade by haemoglobin (CTCAE v6.0) ctcae6_anaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Anaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
World Health Organization 2024 · disagrees: WHO 2024 defines anaemia with fixed population-specific cut-offs (for example <130 g/L men, <120 g/L non-pregnant women) and mild/moderate/severe bands; CTCAE uses the laboratory LLN and its own grades. Encoded separately as who2024_anaemia. CTCAE v5.0 (same body) has identical thresholds.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_anaemia@1.0
Grade 1: Hemoglobin (Hgb) <LLN - 10.0 g/dL; <LLN - 6.2 mmol/L; <LLN - 100 g/L. Grade 2: Hgb <10.0 - 8.0 g/dL; <6.2 - 4.9 mmol/L; <100 - 80 g/L. Grade 3: Hgb <8.0 g/dL; <4.9 mmol/L; <80 g/L; transfusion indicated

v6.0 (2025) · PDF page 4, term 'Anemia' (published July 22, 2025) · source

Review

No review recorded yet.

Blood bilirubin increased, grade, baseline normal (CTCAE v6.0) ctcae6_hyperbilirubinaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hyperbilirubinaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hyperbilirubinaemia@1.0
>ULN - 1.5 x ULN if baseline was normal or less than normal (grade 1); >1.5 - 3.0 x ULN (grade 2); >3.0 - 10.0 x ULN (grade 3); >10.0 x ULN if baseline was normal or less than normal (grade 4)

v6.0 (2025) · PDF page 164, term 'Blood bilirubin increased' (published July 22, 2025) · source

Review

No review recorded yet.

Hypercalcaemia grade by corrected serum calcium (CTCAE v6.0) ctcae6_hypercalcaemia_corrected@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypercalcaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypercalcaemia_corrected@1.0
Corrected serum calcium of >ULN - 11.5 mg/dL; >ULN - 2.9 mmol/L; Ionized calcium >ULN - 1.5 mmol/L (grade 1) ... >11.5 - 12.5 mg/dL; >2.9 - 3.1 mmol/L; Ionized calcium >1.5 - 1.6 mmol/L (grade 2) ... >12.5 - 13.5 mg/dL; >3.1 - 3.4 mmol/L; Ionized calcium >1.6 - 1.8 mmol/L (grade 3) ... >13.5 mg/dL; >3.4 mmol/L; Ionized calcium >1.8 mmol/L (grade 4)

v6.0 (2025) · PDF page 176, term 'Hypercalcemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypercalcaemia grade by ionised calcium (CTCAE v6.0) ctcae6_hypercalcaemia_ionised@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypercalcaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypercalcaemia_ionised@1.0
Corrected serum calcium of >ULN - 11.5 mg/dL; >ULN - 2.9 mmol/L; Ionized calcium >ULN - 1.5 mmol/L (grade 1) ... >11.5 - 12.5 mg/dL; >2.9 - 3.1 mmol/L; Ionized calcium >1.5 - 1.6 mmol/L (grade 2) ... >12.5 - 13.5 mg/dL; >3.1 - 3.4 mmol/L; Ionized calcium >1.6 - 1.8 mmol/L (grade 3) ... >13.5 mg/dL; >3.4 mmol/L; Ionized calcium >1.8 mmol/L (grade 4)

v6.0 (2025) · PDF page 176, term 'Hypercalcemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hyperkalaemia grade by serum potassium (CTCAE v6.0) ctcae6_hyperkalaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hyperkalaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
UK Kidney Association 2026 · disagrees: UKKA bands (mild 5.5-5.9, moderate 6.0-6.4, severe ≥6.5) do not line up with CTCAE grades (>5.5-6.0, >6.0-7.0, >7.0); a value of exactly 5.5 is CTCAE grade 1 but UKKA mild. Encoded separately as ukka2026_hyperkalaemia. CTCAE v5.0 has identical thresholds.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hyperkalaemia@1.0
Grade 1: >ULN - 5.5 mmol/L. Grade 2: >5.5 - 6.0 mmol/L; intervention initiated. Grade 3: >6.0 - 7.0 mmol/L; hospitalization indicated. Grade 4: >7.0 mmol/L; life-threatening consequences

v6.0 (2025) · PDF page 177, term 'Hyperkalemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypermagnesaemia grade by serum magnesium (CTCAE v6.0) ctcae6_hypermagnesaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypermagnesaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypermagnesaemia@1.0
Grade 1: >ULN - 3.0 mg/dL; >ULN - 1.23 mmol/L. Grade 2: -. Grade 3: >3.0 - 8.0 mg/dL; >1.23 - 3.30 mmol/L. Grade 4: >8.0 mg/dL; >3.30 mmol/L; life-threatening consequences

v6.0 (2025) · PDF page 177, term 'Hypermagnesemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypernatraemia grade by serum sodium (CTCAE v6.0) ctcae6_hypernatraemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypernatraemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypernatraemia@1.0
Grade 1: >ULN - 150 mmol/L. Grade 2: >150 - 155 mmol/L; intervention initiated. Grade 3: >155 - 160 mmol/L; hospitalization indicated. Grade 4: >160 mmol/L; life-threatening consequences

v6.0 (2025) · PDF page 177, term 'Hypernatremia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypertriglyceridaemia grade (CTCAE v6.0) ctcae6_hypertriglyceridaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypertriglyceridaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
National Heart, Lung, and Blood Institute (NIH Publication No. 01-3670) 2001 · partly agrees: Both start abnormal at 150 mg/dL and both use 500 mg/dL as a boundary, but ATP III puts 500 in 'very high' while CTCAE puts 500 in grade 2 (>300-500). Encoded separately as atp3_triglycerides.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypertriglyceridaemia@1.0
Grade 1: 150 mg/dL - 300 mg/dL; 1.71 mmol/L - 3.42 mmol/L. Grade 2: >300 mg/dL - 500 mg/dL; >3.42 mmol/L - 5.7 mmol/L. Grade 3: >500 mg/dL - 1000 mg/dL; >5.7 mmol/L - 11.4 mmol/L. Grade 4: >1000 mg/dL; >11.4 mmol/L; life-threatening consequences

v6.0 (2025) · PDF page 178, term 'Hypertriglyceridemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypoalbuminaemia grade by serum albumin (CTCAE v6.0) ctcae6_hypoalbuminaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypoalbuminaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypoalbuminaemia@1.0
Grade 1: <LLN - 3 g/dL; <LLN - 30 g/L. Grade 2: <3 - 2 g/dL; <30 - 20 g/L. Grade 3: <2 g/dL; <20 g/L. Grade 4: Life-threatening consequences; urgent intervention indicated

v6.0 (2025) · PDF page 179, term 'Hypoalbuminemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypocalcaemia grade by corrected serum calcium (CTCAE v6.0) ctcae6_hypocalcaemia_corrected@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypocalcaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypocalcaemia_corrected@1.0
Corrected serum calcium of <LLN - 8.0 mg/dL; <LLN - 2.0 mmol/L; Ionized calcium <LLN - 1.0 mmol/L (grade 1) ... <8.0 - 7.0 mg/dL; <2.0 - 1.75 mmol/L; Ionized calcium <1.0 - 0.9 mmol/L (grade 2) ... <7.0 - 6.0 mg/dL; <1.75 - 1.5 mmol/L; Ionized calcium <0.9 - 0.8 mmol/L (grade 3) ... <6.0 mg/dL; <1.5 mmol/L; Ionized calcium <0.8 mmol/L (grade 4)

v6.0 (2025) · PDF page 179, term 'Hypocalcemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypocalcaemia grade by ionised calcium (CTCAE v6.0) ctcae6_hypocalcaemia_ionised@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypocalcaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypocalcaemia_ionised@1.0
Corrected serum calcium of <LLN - 8.0 mg/dL; <LLN - 2.0 mmol/L; Ionized calcium <LLN - 1.0 mmol/L (grade 1) ... <8.0 - 7.0 mg/dL; <2.0 - 1.75 mmol/L; Ionized calcium <1.0 - 0.9 mmol/L (grade 2) ... <7.0 - 6.0 mg/dL; <1.75 - 1.5 mmol/L; Ionized calcium <0.9 - 0.8 mmol/L (grade 3) ... <6.0 mg/dL; <1.5 mmol/L; Ionized calcium <0.8 mmol/L (grade 4)

v6.0 (2025) · PDF page 179, term 'Hypocalcemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypoglycaemia grade by glucose (CTCAE v6.0) ctcae6_hypoglycaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypoglycaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
American Diabetes Association Professional Practice Committee 2026 · disagrees: ADA levels (level 1 <70 and ≥54 mg/dL, level 2 <54 mg/dL) differ from CTCAE grades (grade 2 begins below 55 mg/dL). Encoded separately as ada2026_hypoglycaemia.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypoglycaemia@1.0
Grade 1: <LLN - 55 mg/dL; <LLN - 3.0 mmol/L. Grade 2: <55 - 40 mg/dL; <3.0 - 2.2 mmol/L. Grade 3: <40 - 30 mg/dL; <2.2 - 1.7 mmol/L. Grade 4: <30 mg/dL; <1.7 mmol/L; life-threatening consequences; seizures

v6.0 (2025) · PDF page 179, term 'Hypoglycemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypokalaemia grade by serum potassium (CTCAE v6.0) ctcae6_hypokalaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypokalaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypokalaemia@1.0
Grade 1: <LLN - 3.0 mmol/L. Grade 2: Symptomatic with <LLN - 3.0 mmol/L; intervention indicated. Grade 3: <3.0 - 2.5 mmol/L; hospitalization indicated. Grade 4: <2.5 mmol/L; life-threatening consequences

v6.0 (2025) · PDF page 180, term 'Hypokalemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hypomagnesaemia grade by serum magnesium (CTCAE v6.0) ctcae6_hypomagnesaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypomagnesaemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hypomagnesaemia@1.0
Grade 1: <LLN - 1.2 mg/dL; <LLN - 0.5 mmol/L. Grade 2: <1.2 - 0.9 mg/dL; <0.5 - 0.4 mmol/L. Grade 3: <0.9 - 0.7 mg/dL; <0.4 - 0.3 mmol/L. Grade 4: <0.7 mg/dL; <0.3 mmol/L; life-threatening consequences

v6.0 (2025) · PDF page 180, term 'Hypomagnesemia' (published July 22, 2025) · source

Review

No review recorded yet.

Hyponatraemia grade by serum sodium (CTCAE v6.0) ctcae6_hyponatraemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hyponatraemia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
European Society of Intensive Care Medicine, European Society of Endocrinology and European Renal Association – European Dialysis and Transplant Association (ERBP) 2014 · partly agrees: The ESE/ESICM/ERA-EDTA guideline fixes the threshold at <135 mmol/L; CTCAE uses the laboratory LLN (often 135). Their severity bands were not opened (encoded separately as ese2014_hyponatraemia, presence only). CTCAE v5.0 prints the same numbers as '125-129' and '120-124'.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_hyponatraemia@1.0
Grade 1: <LLN - 130 mmol/L. Grade 2: 125 - <130 mmol/L and asymptomatic. Grade 3: 125 - <130 mmol/L symptomatic; 120 - <125 mmol/L regardless of symptoms. Grade 4: <120 mmol/L; life-threatening consequences

v6.0 (2025) · PDF page 180, term 'Hyponatremia' (published July 22, 2025) · source

Review

No review recorded yet.

INR increased, grade, not on anticoagulation (CTCAE v6.0) ctcae6_inr_increased@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Elevated INR
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_inr_increased@1.0
Grade 1: >1.2 - 1.5; >1 - 1.5 x baseline if on anticoagulation; monitoring only indicated. Grade 2: >1.5 - 2.5; >1.5 - 2.5 x baseline if on anticoagulation. Grade 3: >2.5; >2.5 x baseline if on anticoagulation; bleeding

v6.0 (2025) · PDF page 169, term 'INR increased' (published July 22, 2025) · source

Review

No review recorded yet.

White blood cell decreased, grade (CTCAE v6.0) ctcae6_leukopenia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Leukopenia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_leukopenia@1.0
Grade 1: <LLN - 3000/mm3; <LLN - 3.0 x 10^9/L. Grade 2: <3000 - 2000/mm3; <3.0 - 2.0 x 10^9/L. Grade 3: <2000 - 1000/mm3; <2.0 - 1.0 x 10^9/L. Grade 4: <1000/mm3; <1.0 x 10^9/L

v6.0 (2025) · PDF page 173, term 'White blood cell decreased' (published July 22, 2025) · source

Review

No review recorded yet.

Neutrophil count decreased, grade (CTCAE v6.0) ctcae6_neutropenia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Neutropenia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2017 · disagrees: CTCAE v5.0 (same body, not independent) used different bands: grade 1 from the LLN to 1500/mm3 and grade 4 below 500/mm3. v6.0 moved every grade down one band. Encoded separately as ctcae5_neutropenia. No independent body grades neutropenia on this scale.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_neutropenia@1.0
Grade 1: <1500 - 1000/mm3; <1.5 - 1.0 x 10^9/L. Grade 2: <1000 - 500/mm3; <1.0 - 0.5 x 10^9/L. Grade 3: <500 - 100/mm3; <0.5 - 0.1 x 10^9/L. Grade 4: <100/mm3; <0.1 x 10^9/L

v6.0 (2025) · PDF page 170, term 'Neutrophil count decreased' (published July 22, 2025) · source

Review

No review recorded yet.

Platelet count decreased, grade (CTCAE v6.0) ctcae6_thrombocytopenia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Thrombocytopenia
Tier
1
Use here
optional setting (off by default)
Edition
v6.0 (2025)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2017 · disagrees: CTCAE v5.0 (same body, not independent): grade 3 down to 25,000/mm3 and grade 4 below 25,000/mm3; v6.0 moved the grade 3/4 boundary to 10,000/mm3. Encoded separately as ctcae5_thrombocytopenia.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).

National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services), Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)

ctcae6_thrombocytopenia@1.0
Grade 1: <LLN - 75,000/mm3; <LLN - 75.0 x 10^9/L. Grade 2: <75,000 - 50,000/mm3; <75.0 - 50.0 x 10^9/L. Grade 3: <50,000 - 10,000/mm3; <50.0 - 10.0 x 10^9/L; transfusion indicated. Grade 4: <10,000/mm3; <10.0 x 10^9/L; life-threatening consequences; urgent intervention indicated

v6.0 (2025) · PDF page 8, term 'Platelet count decreased' (published July 22, 2025) · source

Review

No review recorded yet.

Vitamin D deficiency and insufficiency by 25(OH)D (Endocrine Society 2011) es2011_vitamin_d@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Vitamin D deficiency
Tier
1
Use here
not run by default: Bodies disagree and the society's current edition (2024) declined to set a deficiency level; contested, not run by default.
Edition
2011 (2011) (a newer edition exists)
Second source
Institute of Medicine committee (J Clin Endocrinol Metab 2011;96:53-58) 2011 · disagrees: IOM treats 20 ng/mL as sufficient for 97.5% of the population, so 20-29 ng/mL is not 'insufficient' by IOM; encoded separately as iom2011_vitamin_d.
Contested
yes: Thresholds disagree between bodies: the IOM (2011) found 20 ng/mL (50 nmol/L) covers the needs of 97.5% of the population and warned that inadequacy was overestimated; the Endocrine Society 2011 called <20 deficiency and 21-29 insufficiency; the Endocrine Society 2024 declined to set a target level.

Endocrine Society, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline

es2011_vitamin_d@1.0
Vitamin D deficiency is defined as a 25(OH)D below 20 ng/ml (50 nmol/liter), and vitamin D insufficiency as a 25(OH)D of 21–29 ng/ml (525–725 nmol/liter)

2011 (2011) · Recommendation 1.2 · source

Review

No review recorded yet.

Office blood pressure categories: non-elevated, elevated, hypertension (ESC 2024) esc2024_office_bp@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypertension
Tier
1
Use here
alternative beside blood_pressure: Disagrees with the primary (nhlbi_bp_categories: 130/80 vs 140/90); shown only as 'another published definition gives'.
Edition
2024 (2024)
Second source
National Heart, Lung, and Blood Institute 2025 · disagrees: US categories start hypertension at 130/80; ESC at 140/90. The ESH 2023 guideline could not be opened (HTTP 402).
Contested
yes: Differs from AHA/ACC (hypertension from 130/80; elevated defined by systolic 120-129 only).

European Society of Cardiology, 2024 ESC Guidelines for the management of elevated blood pressure and hypertension

esc2024_office_bp@1.0
The 2024 Guidelines continue to define hypertension as office systolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. Elevated BP is defined as an office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg.

2024 (2024) · Section 5.1, Table 5 (office BP) · source

Review

No review recorded yet.

Hyponatraemia, presence only (ESE/ESICM/ERA-EDTA 2014) ese2014_hyponatraemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hyponatraemia
Tier
1
Use here
default set (sodium)
Edition
2014 (2014) (currency not confirmed)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · partly agrees: CTCAE starts at the laboratory LLN, which is often but not always 135 mmol/L.
Contested
no: The <135 mmol/L definition is widely shared; CTCAE uses the laboratory LLN instead.

European Society of Intensive Care Medicine, European Society of Endocrinology and European Renal Association – European Dialysis and Transplant Association (ERBP), Clinical practice guideline on diagnosis and treatment of hyponatraemia

ese2014_hyponatraemia@1.0
Hyponatraemia, defined as a serum sodium concentration <135 mmol/l

2014 (2014) · Abstract · source

Review

No review recorded yet.

ARDS oxygenation severity in intubated patients by PaO2/FiO2 with PEEP ≥5 (New Global Definition 2024, numeric part only) global2024_ards_intubated_pf@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Acute respiratory distress syndrome (oxygenation component)
Tier
1
Use here
default set (oxygenation)
Edition
New Global Definition 2024 (2024)
Second source
ARDS Definition Task Force 2012 · agrees: Same bands (the Berlin abstract does not state the PEEP requirement).
Contested
no: Bands unchanged from Berlin for intubated patients.

American Thoracic Society-led global consensus (Am J Respir Crit Care Med 2024;209(1):37-47), A New Global Definition of Acute Respiratory Distress Syndrome

global2024_ards_intubated_pf@1.0
Mild: 200 < PaO2:FiO2 ⩽ 300 mm Hg ... Moderate: 100 < PaO2:FiO2 ⩽ 200 mm Hg ... Severe: PaO2:FiO2 ⩽ 100 mm Hg ... For all severity categories of intubated ARDS, a minimum PEEP of 5 cm H2O is required.

New Global Definition 2024 (2024) · Table 1 'Diagnostic Criteria for the New Global Definition of ARDS', intubated ARDS and footnote ¶ · source

Review

No review recorded yet.

COPD airflow obstruction grade by post-bronchodilator spirometry (GOLD 2026) gold2026_copd_airflow@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Chronic obstructive pulmonary disease (spirometric grade)
Tier
1
Use here
default set (copd_airflow)
Edition
2026 report (2026)
Second source
none opened · not found: No independent second source (e.g. ATS/ERS) was opened.
Contested
yes: The fixed ratio 0.7 is contested against the lower limit of normal (z-score) approach used by ATS/ERS interpretation standards (not opened); the fixed ratio over-diagnoses in older and under-diagnoses in younger adults.

Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report — Pocket Guide

gold2026_copd_airflow@1.0
In patients with COPD (FEV1/FVC < 0.7): GOLD 1: Mild FEV1 ≥ 80% predicted; GOLD 2: Moderate 50% ≤ FEV1 < 80% predicted; GOLD 3: Severe 30% ≤ FEV1 < 50% predicted; GOLD 4: Very Severe FEV1 < 30% predicted

2026 report (2026) · Figure 2.10 (PDF page 20); key points (PDF page 11) · source

Review

No review recorded yet.

Serum 25(OH)D reference levels for bone health (Institute of Medicine 2011) iom2011_vitamin_d@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Vitamin D status
Tier
1
Use here
not run by default: The source explicitly declined to define deficiency; not run by default.
Edition
2011 dietary reference intakes (2011) (currency not confirmed)
Second source
Endocrine Society 2011 · partly agrees: Both use 20 ng/mL (50 nmol/L) as a boundary; the Endocrine Society calls 21-29 ng/mL insufficient, which the IOM does not.
Contested
yes: See es2011_vitamin_d: bodies disagree; the IOM explicitly declined to set a deficiency cut-point.

Institute of Medicine committee (J Clin Endocrinol Metab 2011;96:53-58, doi:10.1210/jc.2010-2704), The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know

iom2011_vitamin_d@1.0
serum 25OHD levels of 16 ng/ml (40 nmol/liter) cover the requirements of approximately half the population, and levels of 20 ng/ml (50 nmol/liter) cover the requirements of at least 97.5% of the population ... serum 25OHD levels above 50 ng/ml (125 nmol/liter) should raise concerns among clinicians about potential adverse effects

2011 dietary reference intakes (2011) · Section 'Serum 25OHD Levels and Screening' · source

Review

No review recorded yet.

Adult blood pressure categories: normal, elevated, stage 1, stage 2 (NHLBI, as in the 2017/2025 ACC/AHA guidelines) nhlbi_bp_categories@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypertension
Tier
1
Use here
default set (blood_pressure)
Edition
page last updated June 26, 2025 (2025)
Second source
Nephrology Dialysis Transplantation (open-access commentary) 2026 · partly agrees: Confirms the hypertension threshold (130/80) only; the stage table itself was not in the opened commentary.
Contested
yes: European guidelines define hypertension at 140/90 (ESC 2024, encoded separately as esc2024_office_bp) while AHA/ACC use 130/80.

National Heart, Lung, and Blood Institute (U.S. National Institutes of Health), High Blood Pressure — Diagnosis

nhlbi_bp_categories@1.0
Normal: Less than 120 systolic AND Less than 80 diastolic; Elevated: 120 to 129 AND Less than 80; Stage 1: 130 to 139 OR 80 to 89; Stage 2: 140 or higher OR 90 or higher; Hypertensive Crisis: Higher than 180 OR Higher than 120

page last updated June 26, 2025 (2025) · Blood pressure categories table · source

Review

No review recorded yet.

Serum lactate above the Sepsis-3 septic-shock threshold (numeric component only) sepsis3_septic_shock_lactate@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Septic shock (lactate component)
Tier
1
Use here
default set (lactate)
Edition
Sepsis-3 (2016) (2016)
Second source
none opened · not found: No independent second source was opened for this threshold.
Contested
no: The CMS SEP-1 measure and the Surviving Sepsis Campaign use lactate thresholds for other purposes (for example ≥4 mmol/L); those documents were not opened for this entry.

Society of Critical Care Medicine and European Society of Intensive Care Medicine task force (JAMA 2016;315:801-810), The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

sepsis3_septic_shock_lactate@1.0
persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation

Sepsis-3 (2016) (2016) · Box 3 'New Terms and Definitions' · source

Review

No review recorded yet.

Heart failure category by LVEF: HFrEF, HFmrEF, HFpEF, HFimpEF (Universal Definition 2021) uhf2021_hf_ef_category@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Heart failure (EF category)
Tier
1
Use here
default set (heart_failure_ef)
Edition
2021 (2021) (currency not confirmed)
Second source
none opened · not found: The co-published Eur J Heart Fail 2021;23:352-380 abstract (PMID:33605000) states the same cut-offs but is the same document, not an independent source. The 2022 AHA/ACC/HFSA guideline abstract does not state them; its full text was not opened.
Contested
no: The same cut-offs appear in the co-published Eur J Heart Fail and J Card Fail versions; some guidelines describe HFmrEF differently in wording only (not opened).

HFSA, HFA-ESC and JHFS (J Card Fail 2021;27:387-413, doi:10.1016/j.cardfail.2021.01.022), Universal Definition and Classification of Heart Failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

uhf2021_hf_ef_category@1.0
HF with reduced EF (HFrEF): HF with an LVEF of ≤40%; HF with mildly reduced EF (HFmrEF): HF with an LVEF of 41% to 49%; HF with preserved EF (HFpEF): HF with an LVEF of ≥50%; and HF with improved EF (HFimpEF): HF with a baseline LVEF of ≤40%, a ≥10-point increase from baseline LVEF, and a second measurement of LVEF of >40%.

2021 (2021) · Abstract (Europe PMC record of PMID:33663906) · source

Review

No review recorded yet.

Hyperkalaemia and its severity (UK Kidney Association, July 2026 update) ukka2026_hyperkalaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hyperkalaemia
Tier
1
Use here
default set (potassium)
Edition
updated July 2026 (2026)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · disagrees: CTCAE uses different bands; the UKKA text states its 5.5 mmol/L threshold comes from the European Resuscitation Council guideline, which was not opened.
Contested
yes: The guideline itself says 'There is no universally accepted definition of hyperkalaemia'; it adopts the ERC threshold of 5.5 mmol/L. CTCAE grades differ (see ctcae6_hyperkalaemia).

UK Kidney Association, Clinical Practice Guidelines: Treatment of Acute Hyperkalaemia in Adults

ukka2026_hyperkalaemia@1.0
It is further classified by severity into mild (5.5-5.9 mmol/l), moderate (6.0-6.4 mmol/l) or severe (≥ 6.5 mmol/l).

updated July 2026 (2026) · Introduction, document page 9 (PDF page 10) · source

Review

No review recorded yet.

Osteoporosis and osteopenia by BMD T-score (WHO 1994) who1994_osteoporosis@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Osteoporosis / osteopenia
Tier
1
Use here
default set (bone_density)
Edition
WHO Technical Report Series 843 (1994) (1994) (currency not confirmed)
Second source
none opened · not found: ISCD official positions and national guidelines that restate the categories were not opened.
Contested
yes: T-score categories were defined for postmenopausal (white) women; their use in men and other populations relies on later bodies (e.g. ISCD), which were not opened; the report itself calls cut-off values 'somewhat arbitrary'.

World Health Organization, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group (WHO Technical Report Series 843)

who1994_osteoporosis@1.0
Normal. A value for BMD or BMC within 1 SD of the young adult reference mean. Low bone mass (osteopenia). ... more than 1 SD below the young adult mean but less than 2.5 SD below this value. Osteoporosis. ... 2.5 SD or more below the young adult mean.

WHO Technical Report Series 843 (1994) (1994) · Section 2.1 Definitions, printed pages 5-6 (PDF pages 11-12) · source

Review

No review recorded yet.

Iron deficiency by serum ferritin (WHO 2020) who2020_iron_deficiency_ferritin@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Iron deficiency
Tier
1
Use here
default set (ferritin)
Edition
2020 (2020)
Second source
none opened · not found: No independent source with the same cut-offs was opened.
Contested
yes: Ferritin cut-offs for iron deficiency vary widely between bodies and studies (the guideline's own review cites thresholds from <12 to <30 µg/L in pregnancy); WHO's are low (high specificity). Other bodies (e.g. gastroenterology guidance) use higher values; those texts were not opened.

World Health Organization, WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations

who2020_iron_deficiency_ferritin@1.0
Table 1, iron deficiency, serum ferritin (µg/L): Children under 5 years <12 (apparently healthy), <30 (infection or inflammation); Adults (20–59 years) <15, <70; Pregnant women <15 (first trimester)

2020 (2020) · Executive summary, recommendations 1.1-1.2 (PDF page 11) and Table 1 (PDF page 12) · source

Review

No review recorded yet.

Anaemia and its severity by haemoglobin (WHO 2024) who2024_anaemia@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Anaemia
Tier
1
Use here
default set (haemoglobin)
Edition
2024 (2024)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · partly agrees: CTCAE v6.0 also uses 80 g/L as a severity boundary (grade 3 <80 g/L, WHO severe <80 g/L for adults) but defines the start of anaemia by the laboratory LLN, not fixed WHO cut-offs. No independent source repeating the WHO 2024 table was opened.
Contested
yes: Cut-offs are 5th percentiles of mostly higher-income populations (WHO's own remark); the men's 130 g/L cut-off and severity percentages were debated by the guideline group; CTCAE and laboratory reference ranges use other limits; older adults (>65) are not covered.

World Health Organization, Guideline on haemoglobin cutoffs to define anaemia in individuals and populations

who2024_anaemia@1.0
Table 3: Adults, 15–65 years, nonpregnant women: No anaemia ≥120; Mild 110–119; Moderate 80–109; Severe <80. Adults, 15–65, years men: ≥130; 110–129; 80–109; <80 (g/L)

2024 (2024) · Executive summary: Table 2 (PDF page 12), Table 3 (PDF page 13), Table 4 (PDF page 14), Table 5 (PDF page 15) · source

Review

No review recorded yet.

Adult overweight and obesity by BMI (WHO fact sheet) who_adult_bmi@1.0 1 Draft · pending review draft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Obesity / overweight
Tier
1
Use here
alternative beside bmi: Agrees with the primary (cdc_adult_bmi) at 25 and 30 but has no obesity classes; shown only as an alternative.
Edition
fact sheet dated 7 October 2026 (2026)
Second source
Centers for Disease Control and Prevention 2024 · agrees: Same cut-offs; CDC applies them from age 20.
Contested
yes: As for cdc_adult_bmi: population-specific cut-offs and the limits of BMI as a measure of adiposity.

World Health Organization, Obesity and overweight (fact sheet)

who_adult_bmi@1.0
For adults, WHO defines: overweight is a BMI greater than or equal to 25; and obesity is a BMI greater than or equal to 30.

fact sheet dated 7 October 2026 (2026) · Definitions for adults · source

Review

No review recorded yet.